News

Researchers described the effects of chemotherapy at the single cell resolution in the bone marrow of Myelodysplastic Syndrome patients. The results help better understand which cellular populations are more sensitive to an epigenetic drug.

Researchers from Queen Mary University of London have found that the molecule RvT4 enhances the body’s natural defences against atherosclerosis (hardening of the arteries) in patients with rheumatoid arthritis.

A promising drug could lead to a new treatment for the most aggressive form of breast cancer, which affects thousands of women each year. A pre-clinical study found the new drug successfully inhibits the growth of triple negative breast cancer.

A new "bubble" delivery system for CRISPR-Cas9 could enable cells to undergo gene editing while in the body, in a step towards programmable delivery that eliminates the need to suppress a patient's immune system.

A new therapeutic for stroke based on University of Georgia research will soon enter clinical trials. The U.S. Food and Drug Administration cleared the new drug to enter a Phase 1b/2a clinical trial.

Duke researcher describes an HIV discovery they hope will bring a vaccine across the finish line. Being able to attach an antibody specifically to a structure that would prevent it from popping open would be key.

New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is published in Cardiovascular Diabetology.

Results from a Phase 3 clinical trial show that the vaccine is safe and effective for those aged 2–59 regardless of whether they have previously been infected with dengue.

UVA researchers have identified a promising new drug, using AI, to treat harmful scarring that can occur after heart attacks and other injuries.

A single dose of a CRISPR/Cas9 therapy has been successful in treating hereditary angioedema, reports an initial study of ten patients.